Chinese control percutaneous coronary restenosis after angioplasty and thinking of the progress.docVIP

 PAGE \* MERGEFORMAT 29 Chinese control percutaneous coronary restenosis after angioplasty and thinking of the progress [Keywords:] Percutaneous coronary angioplasty restenosis Summary of Chinese medicine Percutaneous coronary angioplasty (PTCA) is the treatment of cardiovascular disease in the history of a major revolution, it can significantly reduce symptoms and improve prognosis. However, the incidence of restenosis after PTCA remains a long-term effect of the main issues. Intimal of vascular smooth muscle cells (VSMC) proliferation is an important restenosis after PTCA pathophysiological basis. At present, the prevention of the occurrence of restenosis after PTCA is a hot issue in the field of cardiovascular disease, but so far there have yet to see a good effect methods and drugs. medicine with multi-component, multi-effect characteristics. studies show that a variety of traditional Chinese medicine to inhibit VSMC proliferation, capable of PTCA restenosis effective multi-target, multi-directional adjustment. I reviewed our In recent years, prevention and treatment using traditional Chinese medicine research progress restenosis after PTCA, and the existing problems and countermeasures are analyzed in order to control for Chinese medicine research restenosis after PTCA some reference ideas. 1 with anti-restenosis after angioplasty and the role of the main active ingredients of traditional Chinese medicine TMP 1.1 TMP is extracted from the rhizome chuanxiong alkaloid isolated monomers. PTCA or PTCA with stent reported after treatment, patients treated with oral TMP restenosis rate. Cytological experiments confirmed that TMP can inhibit procollagen in primary cultured VSMC @ 1 (Ⅰ) gene transcription, the synthesis and deposition of extracellular matrix to reduce, inhibit the excessive proliferation of VSMC [1]. Zhang et al [2] also found TMP significantly inhibited VSMC proliferation, cell growth arrest in G0/G1, and reduced platelet-derive